ArticleThe World Allergy Organization journal2026
Temporal associations of BMI transition with metabolic inflammation in allergic rhinitis: A retrospective cohort study.
Article in The World Allergy Organization journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In patients with allergic rhinitis (AR), the dynamic longitudinal association between transition from normal body mass index (BMI) to overweight/obesity and metabolic inflammation remains unclear. Methods: We conducted a retrospective longitudinal cohort study involving 1715 AR patients with normal baseline BMI between 2014 and 2025 at the Affiliated Hospital of Guangdong Medical University in Zhanjiang, Guangdong, China. Using targeted maximum likelihood estimation with time-window analysis, we estimated the average treatment effects of BMI increase on inflammatory and metabolic markers over 1-3 years and quantified risks of metabolic diseases. Results: BMI transition was associated with progressively increased systemic inflammation and persistent metabolic dysregulation. Inflammatory markers showed a time-dependent increase, whereas metabolic abnormalities, characterized by elevated triglycerides and reduced high-density lipoprotein cholesterol, appeared earlier and remained stable. BMI gain was also associated with increased risks of several metabolic diseases, particularly fatty liver disease. Conclusion: In AR patients, transitioning from normal BMI to overweight or obesity was associated with a gradual increase in systemic inflammation and persistent metabolic dysfunction that was associated with increased risks of various metabolic diseases. When implementing weight management for patients with AR, it is recommended to monitor changes in body weight over time and intervene early in the weight gain process.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.